Field evaluation of the efficacy of proprietary repellent formulations with IR3535® and Picaridin against Aedes aegypti

Institute of Medical Microbiology, Immunology and Parasitology (IMMIP), University Clinic Bonn, Sigmund Freud Street 25, 53105 Bonn, Germany.
Parasitology Research (Impact Factor: 2.1). 07/2007; 101(1):169-77. DOI: 10.1007/s00436-006-0450-2
Source: PubMed


Seven proprietary repellent formulations (3 hydro-alcoholic spray solutions and 4 skin lotions) with active ingredient IR3,535 (ethyl butylacetylaminopropionate, EBAAP) or Picaridin (hydroxyethyl isobutyl piperidine carboxylate, KBR 3,023, Bayrepel) were tested in a field study on 10 test persons over a period of 10 h for their efficacy at preventing bites. The tests were conducted in Belo Horizonte, Brazil on field populations of the yellow fever mosquito Aedes aegypti. The concentration of the active substances ranged from 10% to 20%. All the tested samples provided lasting protection (time to first bite) over several hours: ranging from 5 h 20 min to 6 h 50 min with a mean of approximately 6 h. The longest protection until the second bite (=first confirmation bite) was approximately 7 h 40 min, whereas the shortest protection was 6 h 50 min. The longest protection until the third bite (=second confirmation bite) was 8 h 35 min, whereas the shortest protection was 7 h 40 min. In the control tests in which none of the samples were applied, the mean times until the first, second and third bites were 26, 46 and 59 min, respectively. The basis for this field study was provided by two American guidelines, which have the greatest international acceptance. The first is a draft guideline from the Environmental Protection Agency (EPA (United States Environmental Protection Agency), Product performance test guidelines. OPPTS 810.3700. Insect repellents for human skin and outdoor premises. Public Draft, 1999) and the second is a standard from the American Society for Testing and Materials (ASTM (American Society for Testing and Materials International), E 939-94 (reapproved 2,000): standard test method of field testing topical applications of compounds as repellents for medically important and pest arthropods (including insects, ticks, and mites): I. Mosquitoes, 2,000). Both guidelines recommend measuring the duration of protection until the first and second bites and also determining the relative protection efficacy in terms of a 95% protection level. The ASTM standard permits different repellents to be applied, whereas the EPA guidelines only permit the use of a single repellent (in different concentrations) on the extremities (forearms or lower leg). In the study presented here, to exclude any possibility of different repellents or concentrations of a single repellent having a reciprocal effect on each other, each test person had repellent samples applied to only one of their forearms. The other forearm was used as a control for making comparative checks every hour and for determining the biting pressure. There was no significant difference in protection times between the two active substances.

Download full-text


Available from: Torsten J. Naucke, Sep 19, 2014
  • Source
    • "Since 2000, several newer insect repellents have been registered and approved for civil use in Europe and the US. These include synthetic picaridin (2- (2-hydroxyethyl)-1-piperidinecarboxylic acid 1-methylpropyl ester, Bayrepel ® , Icaridin ® ) and IR3535 ® (ethyl butylacetylaminopropionate ), and natural lemon eucalyptus oil (active ingredient p-menthane 3,8-diol) and Citronella oil (Carroll et al. 2008; Katz et al. 2008; Naucke et al. 2007; Zhu et al. 2008). Recently we reported the percutaneous characteristics of picaridin and oxybenzone in 50% ethanolic solution across human skin and artificial PDMS membrane (Gu and Chen 2009). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Concurrent application of insect repellent picaridin or DEET with sunscreens has become prevalent due to concerns on West Nile virus and skin cancer. The objectives of this study were to characterize the percutaneous permeation of picaridin and sunscreen oxybenzone from commercially available preparations and to compare the differences in permeability between picaridin and DEET in association with oxybenzone. In vitro diffusion studies were carried out to measure transdermal permeation of picaridin and oxybenzone from four different products, using various application concentrations and sequences. Results were then compared to those of repellent DEET and sunscreen oxybenzone under identical conditions. Transdermal permeation of picaridin across human epidermis was significantly lower than that of DEET, both alone and in combination with oxybenzone. Concurrent use resulted in either no changes or suppression of transdermal permeation of picaridin and oxybenzone. This finding was different from concurrent use of DEET and oxybenzone in which a synergistic permeation enhancement was observed. In addition, permeation of picaridin, DEET and oxybenzone across human epidermis was dependent on application concentration, use sequence, and preparation type. It was concluded from this comparative study that picaridin would be a better candidate for concurrent use with sunscreen preparations in terms of minimizing percutaneous permeation of the chemicals.
    Pharmazie 11/2010; 65(11):835-9. DOI:10.1691/ph.2010.0163 · 1.05 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Objective: To present a literature review about the use of insect repellents on children, highlighting the protection against mosquitoes. Data sources: Pubmed and Lilacs databases were searched for articles in English and Portuguese published in the last ten years with the following key-words: "insect repellents", "chil- dren", "mosquitoes", "N,N-dietil-metatoluamida (DEET)". Data synthesis: Concerning topical repellents, DEET, icaridine and natural oil of lemon eucalyptus are effective to prevent mosquito bites in children and adults and have favorable safety profile when used in appropriate concentra - tion. They are generally recommended for children older than two years-old. Physical barriers are essential for infant protection, especially if they are six months old or less, with special interest in the permethrin-treated nets. Conclusions: Mosquitoes are vectors of a variety of infectious and parasitic diseases which annually affect millions of people and cause thousands of deaths world- wide. The combat to mosquitoes includes individual and environmental measures. Topic repellents for children's individual protection demand specific handling attention and knowledge about the ideal product for each age, espe- cially regarding their efficacy and safety.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: OBJETIVO: Apresentar uma revisão bibliográfica sobre o uso de repelentes de insetos em crianças, com ênfase especial na proteção contra mosquitos. FONTES DE DADOS: Realizou-se uma pesquisa bibliográfica nas bases de dados Pubmed e Lilacs, cujos artigos incluíam produtos comercialmente disponíveis no Brasil. Foram selecionados artigos publicados nos últimos dez anos em língua inglesa ou portuguesa, referentes a crianças, obtidos com as seguintes palavras-chave: "insect repellents", "children", "mosquitoes", "N,N-dietil-metatoluamida (DEET)". SÍNTESE DOS DADOS: Entre os repelentes tópicos, DEET, icaridina e óleo natural de eucalipto-limão apresentam, em concentrações adequadas, perfil de segurança favorável e são eficazes na prevenção de picadas de mosquitos em crianças e adultos. Em geral, são indicados para crianças acima de dois anos de idade. Medidas físicas são fundamentais para proteger lactentes jovens, especialmente menores de seis meses, com destaque para o uso de telas com permetrina. CONCLUSÕES: Os mosquitos são vetores de doenças infectoparasitárias que acometem, anualmente, milhões de pessoas no mundo e causam milhares de mortes. O combate aos mosquitos inclui medidas ambientais e de proteção individual. O uso de repelentes tópicos para proteção individual da criança exige cuidados específicos e conhecimento quanto ao produto ideal para cada idade, especialmente quando consideradas sua eficácia e segurança.
    Revista Paulista de Pediatria 01/2009; 27(1). DOI:10.1590/S0103-05822009000100013
Show more